ARTICLE | Company News
Daiichi Sankyo, AstraZeneca deal
September 28, 2015 7:00 AM UTC
AstraZeneca’s MedImmune LLC unit granted Daiichi Sankyo exclusive rights to develop and commercialize FluMist Quadrivalent in Japan. AZ will receive an upfront fee and is eligible for development and sales milestones. AZ will supply FluMist Quadrivalent to Daiichi, which will develop and commercialize the product in the country. ...